Drug company to offer new malaria drug cheaply in AfricaBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7411.360-b (Published 14 August 2003) Cite this as: BMJ 2003;327:360
- Stephen Pincock
British pharmaceutical firm GlaxoSmithKline has announced that it will offer its new antimalarial drug at non-profit prices in Africa, after its approval by British regulators.
The Medicines and Healthcare Products Regulatory Agency has given approval to the combination of chlorproguanil hydrochloride and dapsone, or Lapdap, for uncomplicated Plasmodium falciparum malaria in adults and children weighing over 5 kg.
The company said it would make the drug available at preferential prices across sub-Saharan Africa as soon as local approval has been granted. The cost to …
Log in using your username and password
Log in through your institution
Sign up for a free trial